Yoon replaces 6 ministers ahead of his 3rd year, general election
US deploys fighter jets in S. Korea for air exercise in Singapore
S. Korea's economy grows 0.6% in Q3, unchanged from earlier estimate
S. Korea successfully tests solid-fuel space rocket
Another search targets opposition leader in corruption probe
‘Celltrion’s COVID-19 antibody shot will kill virus in 5 days’
Celltrion chairman pledges treatment to become available from year-endBy Lim Jeong-yeo
Published : Nov. 11, 2020 - 15:52
“In order to put a stop to the pandemic for good, there needs to be both the vaccine and the treatment,” Seo said live on the radio program. “And among treatments, the most potent are antibody treatments, or plasma-derived treatments.”
From a clinical phase 1 trial targeting 18 lightly affected COVID-19 patients, Celltrion’s CT-P59 was shown to kill the SARS-CoV-2 virus in four to five days of the drug administration.
The time consumed for full recovery was 44 percent faster in the group of people given the CT-P59 shot compared to those in the placebo group.
Celltrion’s CT-P59 is anticipated to complete the clinical phase 2 trial by year-end according to the plan, Seo said, upon which the company will apply for conditional use approval with the Ministry of Food and Drug Safety, should the pipeline provide evidence in safety and efficacy.
“Celltrion has already begun producing the drug for as many as 100,000 people,” Seo said.
Because Korea does not have so many confirmed COVID-19 patients, the drug would be sufficient to cover the nation, according to Seo.
“We will apply for the conditional use approval in December,” Seo said.
“Celltrion is planning to manufacture more CT-P59 to provide for as many as 1.5 million to 2 million people, for overseas supply,” he added.
By Lim Jeong-yeo (firstname.lastname@example.org)
Korea unveils plan to tackle ailing mental health
[KH Explains] China ups OLED ante to take over Korean shares
6 outgoing ministers ‘strong candidates’ for general elections: ruling party